Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innoviva, Inc. (NASDAQ: INVA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Innoviva is a diversified healthcare holding company with a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic healthcare investments.
In its SEC reports, Innoviva discusses royalty revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from therapies such as GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the performance of its strategic investment portfolio. Current reports on Form 8-K, for example, furnish quarterly earnings press releases that detail revenue composition, income from operations, changes in fair values of equity and long-term investments, and balance sheet metrics.
For investors following Innoviva’s infectious disease and critical care focus, periodic filings also provide context on regulatory milestones and development programs, such as the New Drug Application for zoliflodacin and its QIDP designation. Proxy statements and related documents can offer additional insight into governance, equity compensation, and capital allocation policies, while registration statements and prospectuses may describe financing activities.
On Stock Titan, each Innoviva filing is accompanied by AI-powered summaries designed to highlight key points, such as changes in royalty streams, trends in IST net product sales, significant investments or licensing transactions, and updates to risk factors. Users can quickly scan recent 10-Q and 10-K reports, review 8-K announcements, and examine Form 4 insider transaction filings to understand how executives and directors are trading INVA shares. Real-time integration with EDGAR helps ensure that new Innoviva filings appear promptly, while AI-generated overviews make dense regulatory documents more accessible to both individual and professional investors.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of 4,360,401 shares of Innoviva Inc. common stock, representing 5.8% of the class as of 12/31/2025. Dimensional reports sole voting power over 4,255,642 shares and sole dispositive power over 4,360,401 shares.
The shares are held by a series of funds and accounts it advises or manages, and Dimensional states that all securities are owned by these funds. Dimensional disclaims beneficial ownership of the securities beyond what is required for Section 13(d) reporting. It also certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva.
Innoviva, Inc. (INVA) reported insider equity activity for its Chief Financial Officer, Stephen Basso, on a Form 4. On November 15, 2025, he acquired 604 shares of common stock at $0 under the Innoviva Employee Stock Purchase Plan. On November 20, 2025, 237 shares of common stock were withheld by Innoviva at $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted equity awards. After these transactions, he directly owned 51,257 shares of Innoviva common stock.
Innoviva, Inc. (INVA)11/20/2025, 992 shares of common stock were withheld by Innoviva at a price of $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted employee equity awards. After this withholding, the reporting person beneficially owned 48,337 shares of Innoviva common stock directly.
Innoviva, Inc. (INVA) reported an insider equity award. The company’s Chief Financial Officer filed a Form 4 showing acquisition of 27,609 shares of common stock on 11/03/2025 at $18.11 per share, bringing holdings to 50,890 shares directly.
The award is a time-vested RSU: 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments thereafter, subject to continued service. Vesting may accelerate upon a qualifying change in control or an involuntary termination within 24 months following such a change, as approved by the Board’s Compensation Committee.
Innoviva, Inc. (INVA) reported insider equity activity. The reporting person acquired 110,436 shares of common stock at $18.11 on November 3, 2025, noted as a time‑vested RSU grant. 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments, subject to continuous service, with accelerated vesting upon specified change‑in‑control conditions.
The filing also shows 1,860 shares acquired at $0 under the Employee Stock Purchase Plan on May 15, 2025. Following the reported transactions, the reporting person beneficially owned 162,276 shares directly.
Innoviva, Inc. reported stronger Q3 2025 results. Total revenue for the three months ended September 30, 2025 was $107.8 million, up from $89.5 million a year ago, driven by $59.9 million in royalty revenue and $47.3 million in net product sales. Net income rose to $89.9 million (diluted EPS $1.08) from $1.2 million (diluted EPS $0.02) in Q3 2024, aided by gains in the fair values of investments.
Year-to-date through Q3 2025, revenue reached $296.7 million with net income of $107.0 million. Cash and cash equivalents were $476.5 million as of September 30, 2025, supported by $142.4 million in operating cash flow for the nine-month period. The company eliminated its current balance on the 2025 convertible notes through conversions totaling $192.5 million to common stock, while long-term debt stood at $257.4 million. Common shares outstanding were 74,769,062 as of October 31, 2025.
Innoviva, Inc. (INVA) furnished an 8-K announcing its quarterly results press release. On November 5, 2025, the company provided a press release covering results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless specifically stated.
Bank of Nova Scotia filed an amended Schedule 13G reporting beneficial ownership of 2,179,005 shares of Innoviva, Inc. common stock, representing
Bank of Nova Scotia reported ownership of 3,585,830 shares of Innoviva, Inc. common stock, representing 5.55% of the class, on a Schedule 13G/A filing. The bank identifies itself as a parent holding company organized in Canada and states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva. The filing lists sole voting and dispositive power over the reported shares and supplies Innoviva's principal executive office address.
Insider sale via tax-withholding reduced holdings. Innoviva CFO Stephen Basso reported a disposition of 237 shares of Common Stock on 08/20/2025 at a reported price of $19.95 per share. The filing states the shares were withheld by the issuer to satisfy income tax withholding obligations tied to the quarterly vesting of previously granted employee equity awards. After the transaction Mr. Basso beneficially owned 23,281 shares directly. The form is signed and dated 08/22/2025.
FAQ
What is the current stock price of Innoviva (INVA)?
What is the market cap of Innoviva (INVA)?
